keyword
MENU ▼
Read by QxMD icon Read
search

IL-17 and psoriasis

keyword
https://www.readbyqxmd.com/read/28530223/tweak-mediates-inflammation-in-experimental-atopic-dermatitis-and-psoriasis
#1
Daniel Sidler, Ping Wu, Rana Herro, Meike Claus, Dennis Wolf, Yuko Kawakami, Toshiaki Kawakami, Linda Burkly, Michael Croft
Atopic dermatitis (AD) and psoriasis are driven by alternate type 2 and type 17 immune responses, but some proteins might be critical to both diseases. Here we show that a deficiency of the TNF superfamily molecule TWEAK (TNFSF12) in mice results in defective maintenance of AD-specific T helper type 2 (Th2) and psoriasis-specific Th17 cells in the skin, and impaired expression of disease-characteristic chemokines and cytokines, such as CCL17 and TSLP in AD, and CCL20 and IL-19 in psoriasis. The TWEAK receptor, Fn14, is upregulated in keratinocytes and dermal fibroblasts, and TWEAK induces these cytokines and chemokines alone and in synergy with the signature T helper cytokines of either disease, IL-13 and IL-17...
May 22, 2017: Nature Communications
https://www.readbyqxmd.com/read/28521565/interleukin-17-inhibition-role-in-psoriasis-and-inflammatory-bowel-disease
#2
Megan Hohenberger, Leah A Cardwell, Elias Oussedik, Steven R Feldman
INTRODUCTION: Interleukin 17 (IL-17) antagonism provides a highly effective approach for treating psoriasis. Exacerbations of inflammatory bowel disease have been reported in anti-IL-17 psoriasis trials. AIM: To characterize the relationship between IL-17 inhibition and inflammatory bowel disease. METHODS: A review of English-language articles was performed. Search terms included IL-17, psoriasis, inflammatory bowel disease, secukinumab, ixekizumab, and brodalumab...
May 18, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28509526/paraoxonases-and-psoriasis-negative-imbalance-of-anti-oxidant-endogenous-mechanisms
#3
Maria Schiattarella, Giuseppina Caiazzo, Roberta DI Caprio, Serena Lembo, Annunziata Raimondo, Fabio Ayala, Nicola Balato, Giuseppe Monfrecola, Giuliana Fortunato, Anna Balato
BACKGROUNG: Numerous reports have shown that psoriasis patients are more exposed to lipoprotein peroxidation and to a decrease in the activity of paraoxonase (PON)1, an anti-oxidant and anti-inflammatory enzyme. Thus, it has been suggested that malfunction of the anti-oxidant system and an increased production of reactive oxygen species drive immune inflammatory events, that result in progressive skin cell damage in patients with psoriasis. The PON protein family, including PON1, PON2 and PON3, is one of the most important endogenous defense mechanisms against oxidative stress...
May 16, 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/28499587/the-phosphodiesterase-4-inhibitor-apremilast-inhibits-th1-but-promotes-th17-responses-induced-by-6-sulfo-lacnac-slan-dendritic-cells
#4
Stephanie Oehrl, Hridayesh Prakash, Annette Ebling, Nina Trenkler, Priscila Wölbing, Anja Kunze, Thomas Döbel, Marc Schmitz, Alexander Enk, Knut Schäkel
BACKGROUND: The phosphodiesterase 4 (PDE4) inhibitor apremilast increases cellular cAMP levels and has proven effective in the treatment of psoriasis and psoriasis arthritis. We recently described 6-sulfo LacNAc dendritic cells (slanDCs) as immature DCs in blood and as a subset of inflammatory dermal DCs in psoriasis with a pronounced capacity to produce proinflammatory cytokines and to program Th17/Th1 T cell responses. OBJECTIVE: The aim of this study was to investigate possible immune regulatory effects of the PDE4 inhibitor apremilast on slanDCs...
April 20, 2017: Journal of Dermatological Science
https://www.readbyqxmd.com/read/28499194/quercetin-ameliorates-imiquimod-induced-psoriasis-like-skin-inflammation-in-mice-via-the-nf-%C3%AE%C2%BAb-pathway
#5
Haiming Chen, Chuanjian Lu, Huazhen Liu, Maojie Wang, Hui Zhao, Yuhong Yan, Ling Han
Quercetin (QC) is a dietary flavonoid abundant in many natural plants. A series of studies have shown that it has been shown to exhibit several biological properties, including anti-inflammatory, anti-oxidant, cardio-protective, vasodilatory, liver-protective and anti-cancer activities. However, so far the possible therapeutic effect of QC on psoriasis has not been reported. The present study was undertaken to evaluate the potential beneficial effect of QC in psoriasis using a generated imiquimod (IMQ)-induced psoriasis-like mouse model, and to further elucidate its underlying mechanisms of action...
May 9, 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/28485176/the-role-of-il-17-in-the-treatment-of-psoriatic-arthritis
#6
Ennio Lubrano, Fabio Massimo Perrotta
Psoriatic arthritis (PsA) is a chronic inflammatory articular disease characterized by psoriasis, synovitis and enthesitis. Current treatment of PsA is mainly based on the use of classical and biological DMARDs; however, 30-40% of patients could not respond to these or have a loss of response. Areas covered: Recently, the discovery of new pathogenic mechanisms have made possible the development of new drugs that target the IL-17 with the possibility to interfere with the Th17 cells that are considered the cell type mainly involved in the development of the inflammation in PsA...
May 9, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28482118/autoantigens-adamtsl5-and-ll37-are-significantly-upregulated-in-active-psoriasis-and-localized-with-keratinocytes-dendritic-cells-and-other-leukocytes
#7
Judilyn Fuentes-Duculan, Kathleen M Bonifacio, Jason E Hawkes, Norma Kunjravia, Inna Cueto, Xuan Li, Juana Gonzalez, Sandra Garcet, James G Krueger
Psoriasis is a common immune-mediated disease that affects 2-4% of individuals in North America and Europe. In the past decade, advances in research have led to an improved understanding of immune pathways involved in the pathogenesis of psoriasis and has spurred the development of targeted therapeutics. Recently, three psoriasis autoantigens have been described: cathelicidin (LL37), a disintegrin and metalloprotease domain containing thrombospondin type 1 motif-like 5 (ADAMTSL5), and lipid antigens generated by phospholipase A2 (PLA2) group IVD (PLA2G4D)...
May 8, 2017: Experimental Dermatology
https://www.readbyqxmd.com/read/28477030/correlation-between-microrna-143-in-peripheral-blood-mononuclear-cells-and-disease-severity-in-patients-with-psoriasis-vulgaris
#8
Yi-Zhi Zheng, Chun-Feng Chen, Li-Ying Jia, Tu-Gen Yu, Jie Sun, Xiao-Yong Wang
This study aims to explore the correlation between microRNA-143 (miR-143) expression in peripheral blood mononuclear cells (PBMCs) and disease severity in patients with psoriasis vulgaris. From March 2014 to November 2015, 194 patients with psoriasis vulgaris (102 patients in progressive stage and 92 patients in stable stage) were selected as the case group and 175 healthy people as a control group were enrolled in this study. ELISA was used to detect the levels of IL-17 and VEGF in serum. The qRT-PCR assay was performed to detect the relative expression of miR-143 in PBMCs...
April 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/28469254/immune-checkpoint-protein-vista-critically-regulates-the-il-23-il-17-inflammatory-axis
#9
Na Li, Wenwen Xu, Ying Yuan, Natarajan Ayithan, Yasutomo Imai, Xuesong Wu, Halli Miller, Michael Olson, Yunfeng Feng, Yina H Huang, Mary Jo Turk, Samuel T Hwang, Subramaniam Malarkannan, Li Wang
V-domain Immunoglobulin Suppressor of T cell Activation (VISTA) is an inhibitory immune-checkpoint molecule that suppresses CD4(+) and CD8(+) T cell activation when expressed on antigen-presenting cells. Vsir (-/-) mice developed loss of peripheral tolerance and multi-organ chronic inflammatory phenotypes. Vsir (-/-) CD4(+) and CD8(+) T cells were hyper-responsive towards self- and foreign antigens. Whether or not VISTA regulates innate immunity is unknown. Using a murine model of psoriasis induced by TLR7 agonist imiquimod (IMQ), we show that VISTA deficiency exacerbated psoriasiform inflammation...
May 3, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28461763/emerging-targeted-therapies-for-plaque-psoriasis-impact-of-ixekizumab
#10
REVIEW
Tiana Kazemi, Benjamin Farahnik, John Koo, Kourosh Beroukhim
BACKGROUND: Recent studies into the pathogenesis of psoriasis have identified the importance of interleukin 17 (IL-17) in disease activity and have thus provided a new target for biologic therapy. Ixekizumab, the most recent US Food and Drug Administration (FDA)-approved anti-IL-17 biologic agent, appears to be a promising medication for patients suffering from moderate-to-severe plaque psoriasis. METHODS: We reviewed the results of phase III trials for ixekizumab in order to assess the efficacy, safety, and impact on quality of life of this agent in the treatment of plaque psoriasis...
2017: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/28461524/basic-and-translational-science-a-report-from-the-grappa-2016-annual-meeting
#11
James G Krueger, Bruce Kirkham, Christopher T Ritchlin
Rapid advances in effective treatments for psoriasis and psoriatic arthritis (PsA) have emerged from improved understanding of cell subsets and critical mediators that promote tissue inflammation and destruction. More specifically, increased knowledge of innate immunity and the important involvement of cytokines in the interleukin (IL)-23-IL-17 axis as key mediators of psoriatic plaque and joint inflammation in both psoriasis and PsA have led to new theories of immunopathogenesis. Herein we summarize recent discussions on IL-17-related pathways and their relationship to psoriasis and PsA...
May 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28461105/il-10-producing-bregs-are-impaired-in-psoriatic-arthritis-and-psoriasis-and-inversely-correlate-with-il-17-and-ifn%C3%AE-producing-t-cells
#12
Athanasios Mavropoulos, Areti Varna, Efterpi Zafiriou, Christos Liaskos, Ioannis Alexiou, Aggeliki Roussaki-Schulze, Marianna Vlychou, Christina Katsiari, Dimitrios P Bogdanos, Lazaros I Sakkas
Our aim was to study CD19(+)CD27(+)CD24(high) memory and CD19(+)CD24(high)CD38(high) transitional and IL-10+Breg cells, known to inhibit Th1 and Th17 cells in experimental arthritis, in psoriatic arthritis (PsA) and psoriasis (Ps). Peripheral blood Breg cells from 60 patients with PsA, 50 patients with Ps and 23 healthy controls were analyzed by flow cytometry. IL-17A-producing CD3(+) T cells and IFNγ-producing CD3(+) T cells and activation of p38 MAPK and STAT3 were also studied. CD19(+)CD27(+)CD24(high) and CD19(+)CD24(high)CD38(high) Breg cells were decreased in PsA and Ps...
April 28, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/28460549/pharmacokinetic-drug-evaluation-of-brodalumab-for-the-treatment-of-psoriasis
#13
M Galluzzo, M Talamonti, S D'adamio, L Bianchi
Psoriasis is now understood to also be under the driving influence of the IL-17/IL-23 axis, and the medical breakthrough of novel IL-17 inhibitor medications signals a paradigm shift in the way psoriatic patients are managed medically. Brodalumab, a fully human Chinese hamster ovary cell-derived immunoglobulin G2 (IgG2) anti-IL-17RA monoclonal antibody, is currently the most-developed treatment that binds to the IL-17RA. The authors review and provide updates of efficacy and safety by several studies on brodalumab...
May 9, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28444425/pharmacogenetic-markers-to-predict-the-clinical-response-to-methotrexate-in-south-indian-tamil-patients-with-psoriasis
#14
S Indhumathi, Medha Rajappa, Laxmisha Chandrashekar, P H Ananthanarayanan, D M Thappa, V S Negi
INTRODUCTION: Despite the advent of several new systemic therapies, methotrexate remains the gold standard for the treatment of moderate to severe psoriasis. However, there exists a significant heterogeneity in individual response to methotrexate. There are no consistently reliable markers to predict methotrexate treatment response till date. OBJECTIVES: We aimed to demonstrate the association of certain genetic variants in the HLA (HLA-A2, HLA-B17, and HLA-Cw6) and the non-HLA genes including T-helper (Th)-1, Th-2, Th-17 cytokine genes (IFN-γ, IL-2, IL-4, IL-10, IL-12B, and IL-23R), and T-regulatory gene (FOXP3) with the methotrexate treatment response in South Indian Tamil patients with psoriasis...
April 25, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28439340/the-role-of-il-17-in-the-pathogenesis-and-treatment-of-psoriasis
#15
REVIEW
Joshua A Zeichner, April Armstrong
No abstract text is available yet for this article.
June 2016: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/28422002/treatment-of-psoriasis-with-ustekinumab-improved-skin-tightening-in-systemic-sclerosis
#16
Asako Ichihara, Masatoshi Jinnin, Hironobu Ihn
Systemic sclerosis (SSc) is a chronic autoimmune disease characterised by fibrosis, inflammation and vasculopathy in the skin and internal organs. Recently, several articles described that Th17 cells, IL-23 and IL-17 levels were significantly elevated in the peripheral blood or fibrotic sites of SSc. We report a case of SSc and psoriasis administered ustekinumab, IL-12/IL-23 inhibitor. In this case, the skin tightening was successfully improved and ustekinumab was more effective, even though oral prednisolone (9-12 mg/day) had some effect on skin tightening and arthralgia...
April 19, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28390815/act1-a-psoriasis-susceptibility-gene-playing-its-part-in-keratinocytes
#17
Ryan P Hobbs, Susan H Smith, Spiro Getsios
Unchecked inflammation, impaired keratinocyte differentiation, and heightened host defense responses typify psoriasis. Lambert et al. make clever use of psoriasis patient genetics and whole transcriptome RNA-Seq analysis to implicate Act1 in these seemingly variegated processes by keeping IL-17 receptor signaling in check while supporting differentiation and limiting innate immune responses in human keratinocytes.
April 5, 2017: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/28389592/cutting-edge-selective-oral-rock2-inhibitor-reduces-clinical-scores-in-patients-with-psoriasis-vulgaris-and-normalizes-skin-pathology-via-concurrent-regulation-of-il-17-and-il-10
#18
Alexandra Zanin-Zhorov, Jonathan M Weiss, Alissa Trzeciak, Wei Chen, Jingya Zhang, Melanie S Nyuydzefe, Carmen Arencibia, Seetharam Polimera, Olivier Schueller, Judilyn Fuentes-Duculan, Kathleen M Bonifacio, Norma Kunjravia, Inna Cueto, Jennifer Soung, Roy M Fleischmann, Alan Kivitz, Mark Lebwohl, Margarita Nunez, Johnnie Woodson, Shondra L Smith, Robert F West, Mark Berger, James G Krueger, John L Ryan, Samuel D Waksal
Targeted inhibition of Rho-associated kinase (ROCK)2 downregulates the proinflammatory T cell response while increasing the regulatory arm of the immune response in animals models of autoimmunity and Th17-skewing human cell culture in vitro. In this study, we report that oral administration of a selective ROCK2 inhibitor, KD025, reduces psoriasis area and severity index scores by 50% from baseline in 46% of patients with psoriasis vulgaris, and it decreases epidermal thickness as well as T cell infiltration in the skin...
May 15, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/28386999/psoriatic-cutaneous-inflammation-promotes-human-monocyte-differentiation-into-active-osteoclasts-facilitating-bone-damage
#19
Annunziata Raimondo, Serena Lembo, Roberta Di Caprio, Giovanna Donnarumma, Giuseppe Monfrecola, Nicola Balato, Fabio Ayala, Anna Balato
Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy that can be associated with focal bone erosions. Psoriasis usually precedes the psoriatic arthritis onset by an average of 10 years, but this relation is not yet fully elucidated. Pro-inflammatory cytokines, such as IL-33, OPN, IL-17, and TNF-α are involved in both psoriasis and PsA pathogenesis as well as in bone homeostasis. In this study, we have demonstrated that IL-33, OPN, IL-17, and TNF-α induced the release of a wide range of pro-osteoclastogenic factors from the skin, such as RANKL, that promote monocyte differentiation in osteoclasts...
April 7, 2017: European Journal of Immunology
https://www.readbyqxmd.com/read/28370441/adverse-skin-reaction-to-secukinumab
#20
M F Peigottu, M A Montesu
Psoriasis is a chronic, immune-mediated inflammatory skin disorder affecting about 1 to 3% of the population worldwide (1). The treatment of psoriasis has undergone a revolution with the advent of biologic therapies, including TNF-a inhibitors and interleukin (IL) 12/23 and 17 inhibitors. In 2015, secukinumab was the first IL-17A inhibitor approved for the treatment of moderate-to-severe psoriasis, and more recently for the treatment of ankylosing spondylitis and psoriatic arthritis (2). We report a severe cutaneous reaction to secukinumab that required termination of therapy in a patient non-responder to all biologic drugs approved for the treatment of psoriasis...
March 29, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
keyword
keyword
50079
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"